RECRUITING · INTERVENTIONAL · TREATMENT study · Metastatic Breast Cancer ( HER2 Negative) · Phase 2 · Enrollment 20 · Sponsor: Institut Curie
ClinicalTrials.gov published a clinical update in Oncology on 23 Feb 2026. The item focuses on Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer. Open the detail page to review the full original feed content.